British Medicines Regulatory Authority: “A. Burla misled us by vaccinating children against Covid-19.”

Britain’s Prescription Medicines Compliance Authority (PMCPA) condemned Pfizer CEO Albert Burla’s public remarks about the “benefits” of mass vaccination of children against covid-19 as “misleading claims and unsubstantiated claims”, according to a British newspaper. Telegraph.

Pfizer appealed these findings and said its comments were based on “updated scientific evidence” and can be supported by “publicly available independent benefit-risk assessments.” Pfizer’s appeal was granted.

Dr Albert Burla, in an interview with the BBC last December, stated: “I have no doubt about the benefits of vaccinating children between the ages of five and 11 against covid-19.” He also stated that “the number of cases of covid-19 in schools is on the rise and this is a major concern as there are children with severe symptoms.” The interview was published on December 2, before the vaccine was approved by the UK medical regulator for this age group.

It took a small team of committed individuals a year to get to this point and has taken grit, perseverance and a lot of hard work. No thanks to all those who cast us as the ‘misinformants’ during that time. https://t.co/4PevAQub97

— Molly Kingsley (@lensiseethrough) November 26, 2022

“Excessive advertising and misleading encouragement to vaccinate children”

Following the publication of the interview on the BBC, UsForThem, a British voluntary parental rights organization, filed a complaint with the pharmaceutical regulator, the Prescription Medicines Compliance Authority (PMCPA) in the UK. The complaint explained that Dr. Burla’s comments about vaccinating children were “grossly misleading” and “highly promotional” and claimed that he had violated several points of the Association of the British Pharmaceutical Industry (ABPI) code of practice. “There is no evidence that healthy schoolchildren in the UK are at significant risk of contracting SARS COV-2 and the suggestion that they are at such risk is shamefully misleading,” the complaint said.

In September 2021, the Joint Committee on Vaccinations and Immunization (JCVI) called for mass vaccination of children aged 12-15 years not to be carried out, saying that “the benefit will be very small” and “the health of younger schoolchildren is less at risk of contracting the virus.” Less than two weeks later, however, ministers gave the green light for teens to get a dose of Pfizer-BioNTech, with UK chief medical officers saying it would help keep schools open.

In February 2022, the Joint Committee on Vaccinations and Immunization (JCVI) ruled that children aged 5-11 could be vaccinated, with ministers arguing that parents should ultimately make the decision.

“Updated Science Data”

The Code of Practice Committee convened by the UK Medicines Regulatory Authority (PMCPA) found that Pfizer violated the code for a variety of reasons. In particular, an American multinational pharmaceutical company misled its audience by making unsubstantiated claims and not presenting information in a credible and balanced manner. The UK Medicines Regulatory Agency said a full report on the case will be published in the coming weeks.

However, this is the first time that Pfizer has been convicted, even at first instance, of “misleading” about vaccinating young children. Making a decision at this stage means that much of Britain’s mass vaccination is starting to look bad. Please note that infant mortality has risen sharply since the start of mass covid-19 vaccinations. Data on a 552% increase in mortality in children aged five to fifteen, after the decision EU extending covid-19 vaccination to these age groups is simply shocking.

Now the numbers clearly show that there is a serious problem of increasing mortality, which is associated, at least temporarily, with mass (forced) vaccination. On May 28, 2021, the European Medicines Agency extended the Emergency Use Authorization for Pfizer’s Covid-19 mRNA injection for children aged 12 to 15 years.
Six months later, he extended the emergency use authorization to children aged 5 to 11. Before they did it the first time, child mortality was well below what was expected. Since then, however, its growth has increased exponentially. So much so that by November 6, 2022, infant mortality across Europe has risen by 552%!

Source link